Thermo Fisher Scientific extends partnership with Symphogen to support biopharma
Thermo Fisher and Symphogen extend their collaboration using innovative and efficient workflows to improve data confidence, aiding the creation of new cancer treatments
Thermo Fisher and Symphogen extend their collaboration using innovative and efficient workflows to improve data confidence, aiding the creation of new cancer treatments
Pankaj Patel, Chairman, Zydus Lifesciences; Umang Vohra, CEO, Cipla; G V Prasad, Co-Chairman, Dr Reddy's; Nilesh Gupta, MD, Lupin and Dilip Shanghvi, MD, Sun Pharmaceuticals sharing their vision to outline the roadmap for the industry.
If approved, Opdivo plus chemotherapy would be the first neoadjuvant immunotherapy-based option for patients with resectable non-small cell lung cancer in the U.S.
High level of vaccine efficacy maintained over a 6-month period of surveillance
This collaboration aims at capturing translational disease insights from large external healthcare biobanks and maximizing value of data for drug discovery and precision medicine
The company, already scaling across Europe, plans to accelerate the deployment of its medication reconciliation platform in the United States
Company has bought 7.73 million shares for KRW 146.1 billion thus securing the largest shareholder status in Bukwang Pharmaceutical
Vonjo is the first approved therapy to specifically address the needs of adult cytopenic myelofibrosis patients
BBL will gain Viatris’ global biosimilars business whose revenues are estimated to be USD 1 billion next year, along with its portfolio of in-licensed biosimilar assets
The sNDA was supported by the clinical results from cohort B of a single-arm, multi-center, pivotal study (RELIANCE study) on Carteyva in adult patients with relapsed or refractory B cell non-hodgkin lymphoma in China
Subscribe To Our Newsletter & Stay Updated